RockJPScarpaceLHearshenD: Associations among magnetic rsonance spectroscopy, apparent diffusion coeffocients and image guided histopathology with special attention to radiation necrosis, Neurosurgery54: 1111–1119, 2004.
2.
MacdonaldDRCascinoTLScholdSC: Response criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical Oncology8: 1277–1280, 1990.
3.
HensonJWUlmerSHarrisGJ: Brain tumor imaging in clinical trials, American Journal of Neuroradiology, 29: 419–424, 2008.
4.
GalanisEBucknerJCMaurerMJ: Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods, Neuro-Oncology8: 156–165, 2006.
5.
MandonnetEJbabdiSTaillandierL: Preoperative estimation of residual volume for WHO grade II glioma resected with intraoperative functional mapping. Neuro Oncol9: 63–69, 2007.
6.
DempseyMFCondonBRHadleyDM: Measurement of Tumor “Size” in Recurrent Malignant Glioma: 1D, 2D, or 3D?American Journal of Neuroradiology26: 770–776, 2005.
7.
LambornKRYungWKAChangSM: Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas, Neuro-oncology, April 2008: 162–170.
8.
HeestersMAWijrdemanHKStruikmansH: Brain tumor delineation based on CT and MR imaging. Implications for radiotherapy treatment planning. Strahlenther Onkol169: 729–33, 1993.
9.
BrandesAARigonAMonfardiniS: Radiotherapy of the brain in elderly patients. Contra. Eur J Cancer36: 447–452, 2000.
10.
BrandesAATosoniASpagnolliF: Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. Neuro Oncol Advance9: 2–7; 2008.
11.
BrandsmaDStaplersLTaalW: Clinical features, mechanisms and management of pseudoprogression in malignant gliomas. Lancet Oncol,9: 453–61. 2008.
12.
KumarAJLeedsNEFullerGN: Malignant Gliomas: MR Imaging Spectrum of Radiation Therapy-and Chemotherapy-induced Necrosis of the Brain after Treatment, Radiology217: 377–384, 2000.
13.
StuppRRoilaF: Clinical recommendations: Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnnals of Oncology19: 83–85, 2008.
14.
RabinovJDLeePLBarkerFG: In Vivo 3-T MR Spectroscopy in the Distinction of Recurrent Glioma versus Radiation Effects: Initial Experience Radiology225: 871–879, 2002.
15.
TraberFBlockWFlackeS: 1H-MR Spectroscopy of brain tumors in the course of radiation therapy: use of fast spectroscopic imaging and single-voxel spectroscopy for diagnosing recurrence. Rofo174: 33–42, 2002.
16.
WeybrightPSundgrenPCMalyP: Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol185: 1471–1476, 2005.
17.
SchlemmerHPBachertPHerfarthKK: Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. Am J Neuroradiol22: 1316–1324, 2001.
18.
ZengQ-SLiCh. FLiuH: Distinction between recurrent glioma and radiation injury using magneticresonance spectroscopy in combination with diffusion-weighted imaging, Int. J. Radiation Oncology Biol. Phys68: 151–158, 2007.
19.
AndoKIshikuraRNagamiY: Usefulness of Cho/Cr ratio in proton MR spectroscopy for differentiating residual/recurrent glioma from non-neoplastic lesionsNippon Igaku Hoshasen Gakkai Zasshi64: 121–26, 2004.
20.
LichyMPHenzeMPlathowC: Metabolic imaging to follow stereotactic radiation of gliomas - the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT. Rofo176: 1114–21, 2004.
21.
RockJPHearshenDScarpaceL: Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery51: 912–919, 2002.
22.
GravesEENelsonSJVigneronDB: Serial Proton MR Spectroscopic Imaging of Recurrent Malignant Gliomas after Gamma Knife Radiosurgery. American Journal of Neuroradiology22: 613–624, 2008.
23.
SundgrenPCFanXWeybrightP: Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magnetic Resonance Imaging24: 1131–1142, 2006.
24.
ChenevertTMcKeeverPRossB: Monitoring early response of experimental brain tumors to therapy using diffusion magneticresonance imaging. Clin Cancer Res3: 1457–66, 1997.
25.
ChenevertTStegmanLTaylorJM: Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst92: 2029–36, 2000.
26.
MardorYPfefferRSpiegelmannR: Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol21: 1094–100, 2003.
27.
Dzik-JuraszADomenigCGeorgeM: Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet360: 307–8, 2002.
28.
ProvenzaleJMMukundanSBarboriakDP: Diffusion-weighted and Perfusion MR Imaging for Brain Tumor Characterization and Assessment of Treatment Response Radiology239: 632–649, 2006.
29.
Di ChiroGOldfieldEWrightDC: Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. Am J Roentgenol150: 189–197, 1988.
30.
HaymakerWIbrahimMZMiquelJ: Delayed radiation effects in the brains of monkeys exposed to X-and g-rays. J Neuropathol Exp Neuro27: 50–7, 1968.
31.
SugaharaTKorogYTomiguchiS: Posttherapeutic Intraaxial Brain Tumor: The Value of Perfusion-sensitive Contrast-enhanced MR Imaging for Differentiating Tumor Recurrence from Nonneoplastic Contrast-enhancing Tissue, American Journal of Neuroradiology21: 901–909, 2000.
32.
SugaharaTKorogiYKochiM: Relationship of MR determined cerebral blood volume maps to histologic and angiographic vascularities of gliomas. Am J Roentgenol171: 1479–1485, 1998.
33.
CaoYTsienCINageshV: Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RTInt J Radiat Oncol Biol Phys. 64: 876–885, 2006.
34.
ProvenzaleJM: Imaging of angiogenesis: Clinical Techniques and novel imaging methods, Am J Roentgenol188: 11–23, 2007.
35.
ChenW: Clinical applications of PET in brain tumors. J Nucl Med48: 1468–1481; 2007.
36.
PopperlGGotzCRachingerW: Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging31: 1464–1470, 2004.
